Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: Angiogenic implications for signal transduction therapy of solid tumors

American Journal of Pathology

Volumn 151, Issue 6, 1997, Pages 1523-1530

  Viloria Petit, Alicia M ^a,b   Rak, Janusz ^a   Hung, Mien Chie ^c   Rockwell, Patricia ^d   Goldstein, Neil ^d   Fendly, Brian ^e   Kerbel, Robert S ^a,b,f  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF TEXAS   (United States)

^d ELI LILLY AND COMPANY   (United States)

^e GENENTECH INC   (United States)

^f SUNNYBROOK RESEARCH INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; NEUTRALIZING ANTIBODY; ONCOPROTEIN; TYROSINE KINASE RECEPTOR;

ANIMAL CELL; ARTICLE; CANCER CELL CULTURE; CELL PROLIFERATION; CELL SURVIVAL; CELL TRANSFORMATION; CONTROLLED STUDY; CYTOTOXICITY; HUMAN; HUMAN CELL; MALIGNANT TRANSFORMATION; MOUSE; NONHUMAN; ONCOGENE NEU; PRIORITY JOURNAL; PROTO ONCOGENE; RECEPTOR UPREGULATION; SIGNAL TRANSDUCTION; SOLID TUMOR; TUMOR VASCULARIZATION;

ADENOCARCINOMA; ANIMALS; ANTIBODIES, MONOCLONAL; BREAST NEOPLASMS; CARCINOMA, SQUAMOUS CELL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; ENDOTHELIAL GROWTH FACTORS; EPIDERMAL GROWTH FACTOR; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOENZYME TECHNIQUES; LYMPHOKINES; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; NEOVASCULARIZATION, PATHOLOGIC; NEUTRALIZATION TESTS; RECEPTOR, ERBB-2; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0001223491     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Salomon DS, Brandt R, Ciardiello F, Normanno N: Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 1995, 19:183-232
2. Masui H, Kawamoto T, Sato JD, Wolf B, Sato G, Mendelsohn J: Growth inhibition of human tumor cells in athymic mice by antiepidermal growth factor receptor monoclonal antibodies. Cancer Res 1984, 44:1002-1007
3. Fendly BM, Winget M, Hudziak RM, Lipari MT, Napier MA, Ullrich A: Characterization of murine monoclonal antibodies reactive to either the human epidermal growth factor receptor or HER2/neu gene product. Cancer Res 1990, 50:1550-1558
4. Mendelsohn J, Fan Z: Epidermal growth factor receptor family and chemosensitization. J Natl Cancer Inst 1997, 89:341-343
5. Kohl NE, Omer CA, Conner MW, Anthony NJ, Davide JP, deSolms SJ, Giuliani EA, Gomez RP, Graham SL, Hamilton K, Handt LK, Hartman GD, Koblan KS, Kral AM, Miller PJ, Mosser SD, O'Neill TJ, Rands E, Schaber MD, Gibbs JB, Oliff A: Inhibition of farnesyltransferase induces regression of mammary and salivary carcinomas in ras transgenic mice. Nature Med 1995, 1:792-797
6. Goldstein NI, Prewett M, Zuklys K, Rockwell P, Mendelsohn J. Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clin Cancer Res 1995, 1:1311-1318
7. Tokuda Y, Ohnishi Y, Shimamura K, Iwasawa M, Yoshimura M, Ueyama Y, Tamaoki N, Tajima T, Mitomi T: In vitro and in vivo antitumour effects of a humanised monoclonal antibody against c-erbB-2 product. Br J Cancer 1996, 73:1362-1365
8. Jain RK: Delivery of novel therapeutic agents in tumors: physiological barriers and strategies. J Natl Cancer Inst 1989, 81:570-576
9. Rak J, Mitsuhashi Y, Bayko L, Filmus J, Sasazuki T, Kerbel RS: Mutant ras oncogenes upregulate VEGF/VPF expression: implications for induction and inhibition of tumor angiogenesis Cancer Res 1995, 55:4575-4580
10. Bouck N, Stellmach V, Hsu SC: How tumors become angiogenic. Adv Cancer Res 1996, 69:135-74
11. Ferrara N: The role of vascular endothelial growth factor in pathological angiogenesis. Breast Cancer Res Treat 1995, 36:127-137
12. Goldman CK, Kim J, Wong WL, King V, Brock T, Gillespie GY: Epidermal growth factor stimulates vascular endothelial growth factor production by human malignant glioma cells: a model of glioblastoma multiforme pathophysiology. Mol Biol Cell 1993, 4:121-133
13. Gille J, Swerlick RA, Caughman SW: Transforming growth factor-alpha-induced transcriptional activation of the vascular permeability factor (VPF/NEGF) gene requires AP-2-dependent DNA binding and transactivation. EMBO J 1997, 16:750-759
14. Alon T, Hemo I, Itin A, Pe'er J, Stone J, Keshet E: Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity. Nature Med 1995, 1:1024-1028
15. Benjamin LE, Keshet E: Conditional switching of VEGF expression in tumors: induction of endothelial cell shedding and regression of hemangioblastoma-like vessels by VEGF withdrawal. Proc Natl Acad Sci USA 1997, 94:8761-8766
16. Ferrara N, Carver-Moore K, Chen H, Dowd M, Lu L, O'Shea KS, Powell-Braxton L, Hillan KJ, Moore MW: Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 1996, 380:439-442
17. Cheng SY, Huang HJ, Nagane M, Ji XD, Wang D, Shih CC, Arap W, Huang CM, Cavenee WK: Suppression of glioblastoma angiogenicity and tumorigenicity by inhibition of endogenous expression of vascular endothelial growth factor. Proc Natl Acad Sci U S A 1996, 93: 8502-8507
18. Millauer B, Longhi MP, Plate KH, Shawver LK, Risau W, Ullrich A, Strawn LM: Dominant-negative inhibition of Flk-1 suppresses the growth of many tumor types in vivo. Cancer Res 1996, 56:1615-1620
19. Padhy LC, Shih C, Cowing D, Finkelstein R, Weinberg RA: Identification of a phosphoprotein specifically induced by the transforming DNA of rat neuroblastomas. Cell 1982, 28:865-871
20. Kawamoto T, Sato JD, Le A, Polikoff J, Sato GH, Mendelsohn J: Growth stimulation of A431 cells by epidermal growth factor: identification of high-affinity receptors for epidermal growth factor by an anti-receptor monoclonal antibody. Proc Natl Acad Sci USA 1983, 80:1337-1341
21. . Goldberg MA, Schneider TJ: Similarities between the oxygen-sensing mechanisms regulating the expression of vascular endothelial growth factor and erythropoietin. J Biol Chem 1994, 269:4355-4359
22. Lu C, Sheehan C, Rak JW, Chambers CA, Hozumi N, Kerbel RS: Endogenous interleukin 6 can function as an in vivo growth-stimulatory factor for advanced-stage human melanoma cells. Clin Cancer Res 1996, 2:1417-1425
23. Kokai Y, Myers JN, Wada T, Brown VI, LeVea CM, Davis JG, Dobashi K, Greene MI: Synergistic interaction of p185c-neu and the EGF receptor leads to transformation of rodent fibroblasts. Cell 1989, 58:287-292
24. Folkman J, Watson K, lngber D, Hanahan D: Induction of angiogenesis during transition from hyperplasia to neoplasia. Nature 1989, 339:58-61
25. Grugel S, Finkenzeller G, Weindel K, Barleon B, Marme D: Both v-Ha-ras and v-raf stimulate expression of the vascular endothelial growth factor in NIH 3T3 cells. J Biol Chem 1995, 270:25915-25919
26. Mazure NM, Chen EY, Yeh P, Laderoute KR, Giaccia AJ: Oncogenic transformation and hypoxia synergistically act to modulate vascular endothelial growth factor expression. Cancer Res 1996, 56:3436-3440
27. Arbiser JL, Moses MA, Fernandez CA, Ghiso N, Cao Y, Klauber N, Frank D, Brownlee M, Flynn E, Parangi S, Byers HR, Folkman J: Oncogenic H-ras stimulates tumor angiogenesis by two distinct pathways. Proc Natl Acad Sci USA 1997, 94:861-866
28. Volpert OV, Dameron KM, Bouck N: Sequential development of an angiogenic phenotype by human fibroblasts progressing to tumorigenicity. Oncogene 1997, 14:1495-1502
29. Bargmann CI, Hung MC, Weinberg RA: Multiple independent activations of the neu oncogene by a point mutation altering the transmembrane domain of p185. Cell 1986, 45:649-657
30. Rak J, Filmus J, Kerbel RS: Reciprocal paracrine interactions between tumor cells and endothelial cells: the "angiogenesis progression" hypothesis. Eur J Cancer 1996, 32A:2438-2450
31. Drebin JA, Link VC, Stern DF, Weinberg RA, Greene MI: Down-modulation of an oncogene protein product and reversion of the transformed phenotype by monoclonal antibodies. Cell 1985, 41: 697-706
32. Kohl NE, Mosser SD, deSolms SJ, Giuliani EA, Pompliano DL, Graham SL, Smith RL, Scolnick EM, Oliff A, Gibbs JB: Selective inhibition of ras-dependent transformation by a farnesyltransferase inhibitor. Science 1993, 260:1934-1942
33. Monia BP, Johnston JF, Geiger T, Muller M, Fabbro D: Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against C-raf kinase. Nature Med 1996, 2:668-675
34. Zhang Y, Yu D, Xia W, Hung MC: HER-2/neu-targeting cancer therapy via adenovirus-mediated E1A delivery in an animal model. Oncogene 1995, 10:1947-1954
35. Buchdunger E, Mett H, Trinks W, Regenass U, Muller M, Meyer T, Beilstein P, Wirz B, Schneider P, Traxler P, Lydon NB: 4,5-Bis(4-fluoroanilino)phthalimide: a selective inhibitor of the epidermal growth factor receptor signal transduction pathway with potent in vivo antitumor activity. Clin Cancer Res 1995, 1:813-821
36. Roychowdhury DF, Tseng A, Fu KK, Weinberg V, Weidner N: New prognostic factors in nasopharyngeal carcinoma. Cancer 1996, 77: 1419-1426
37. Ciardiello F, Damiano V, Bianco R, Bianco C, Fontanini G, De Laurentiis M, De Placido S, Mendelsohn J, Bianco AR, Tortora G: Antitumor activity of combined blockade of epidermal growth factor receptor and protein kinase A. J Natl Cancer Inst 1996, 88:1770-1776
38. Rak J, Mitsuhashi Y, Erdos V, Huang S-N, Filmus J, Kerbel RS: Massive programmed cell death in intestinal epithelial cells induced by three-dimensional growth conditions: suppression by expression of a mutant c-H-ras-oncogene. J Cell Biol 1995, 131:1587-1598
39. Lebowitz P, Sakamura D, Prendergast GC: Farnesyl transferase inhibitors induce apoptosis of Ras-transformed cells denied substratum attachment. Cancer Res 1997, 57:708-713